Clinical experience of adalimumab in the treatment of psoriasis - A 10-year journey in a tertiary dermatology centre

Chan, Wai Man Mandy; Oon, Hazel H; Chong, Wei‐Sheng

doi:10.4103/ijdvl.ijdvl_163_17

Cited by 5 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that patients who received biologic treatment showed a trend towards greater improvement in clinical severity scores compared to those who received conventional systemic therapy. The small sample size precludes conclusions regarding clinical safety and efficacy of biologics in our local setting, although the observed clinical responses and side effects are in keeping with previously observed findings in retrospective local cohorts 9,10 international registries 11,12 and systematic reviews 8,13 …”

Section: Discussionsupporting

confidence: 72%

Clinical and patient‐reported outcomes from the first 4 years of a Psoriasis Biologics Registry in Singapore

Koh

Oon

Chong

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index), BSA (body surface area) and PGA (Physician Global Assessment) measures at baseline, demonstrated a statistically non‐significant trend towards greater improvement with treatment, and had a lower percentage of adverse events compared to those receiving conventional systemic therapy. Future analyses of SINGPSOR, with larger sample size and longer follow‐up, will be invaluable to further characterize these patients and their treatment outcomes.

show abstract

Section: Discussionsupporting

confidence: 72%